A choice of a nonsteroidal anti-inflammatory drug with regard to gastrointestinal and cardiovascular risks

Pakhomova I.G.

doi:https://doi.org/10.17116/jnevro20161164185-89

Pakhomova I.G.

Mechnikov Northwestern State Medical University, St. Petersburg

A choice of a nonsteroidal anti-inflammatory drug with regard to gastrointestinal and cardiovascular risks

Authors:

Pakhomova I.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(4): 85‑89

DOI: 10.17116/jnevro20161164185-89

Read: 3226 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Pakhomova IG. A choice of a nonsteroidal anti-inflammatory drug with regard to gastrointestinal and cardiovascular risks. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(4):85‑89. (In Russ.)
https://doi.org/10.17116/jnevro20161164185-89

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Abstract:

NSAIDs are effective drugs among analgesics and antiinflammatory drugs used widely in clinical practice. It is important to emphasize that the range of users of NSAIDs in population are patients with chronic disorders of the joints and spine. However, when prescribing NSAIDs one should consider risk factors of side-effects not only from the gastrointestinal tract, but cardiovascular events as well. The potential negative risks of using NSAIDs promote an active research on creation of new medicinal substances which are able to minimize NSAID-induced complications. The use of oxide-nitrogen-associated NSAIDs, in particular amtolmetin guacil, in patients with risk factors of side-effects from the gastrointestinal tract and cardiovascular system seems to be promising. It is noted that amtolmetin guacil has balanced analgesic and anti-inflammatory effects and is well tolerated.

Keywords:

NSAIDs

NSAID-gastropathy

cardiovascular risk

amtolmetin guacil

Authors:

Pakhomova I.G.

Mechnikov Northwestern State Medical University, St. Petersburg

Close metadata

References:

Classafication of Chronic Pain, second Edition, Part III: Pain Terms, A Current List with Definitions and Notes on Usage, IASP Task Force on Taxonomy. Edited by H. Merskey, N. Bogduk. Seattle, WA: IASP Press, 1994:209-214
Zvartau E.E., Makar'yants M.L. Rational anesthesia in general practice: а practical guide for physicians. Edited by academician of RANS corresponding member of RAMN honored scientist of Russia рrofessor A.M. Vein. - М., 1999: 3-5. (In Russ.)
Zhu K., Devine A., Dick I., Prince R.L. Association of back pain frequency with mortality, coronary heart events, mobility, and quality of life in elderly women. Spine. 2007; 32(18):2012-2018. doi.org/10.1097/brs.0b013e318133fb82
Im H.J., Kim J.S., Li X., Kotwal N, Sumner DR, van Wijnen AJ, Davis FJ, Yan D, Levine B, Henry JL, Desevré J, Kroin JS. Alteration of sensory neurons and spinal response to an experimental osteoarthritis pain model. Arthritis & Rheumatism. 2010; 62(10):2995-3005. doi.org/10.1002/art.27608.
Dembo G., Park S., Kharasch E. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology. 2005; 102 (2): 409–415. doi.org/10.1097/00000542-200502000-00026.
Bianchi M., Martucci C., Ferrario P. Increased Tumor Necrosis Factor-and Prostaglandin E2 Concentrations in the Cerebrospinal Fluid of Rats with Inflammatory Hyperalgesia: The Effects of Analgesic Drugs. Anesthesia & Analgesia. 2007;104:949-954 doi.org/10.1213/01.ane.0000258060.89380.27
Karateev A.E., Nasonova V.A. The development and recurrence of gastric ulcers and duodenal ulcers in patients taking nonsteroidal anti-inflammatory drugs: effects of standard risk factors. Therapevticheskii arkhiv. 2008, 5: 62–66 (In Russ.)
Karateev A.E., Yakhno N.N., Lazebnik L.B., Kukushkin M.L., Drozdov V.N., Isakov V.A., Nasonov E.L. The use of nonsteroidal anti-inflammatory drugs. Clinical practice guidelines. Edited by A.E. Karateev- М.: IМА рress, 2009-167р. (In Russ.)
Solomon D., Sctmeeweiss S., Levin R., Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004; 44: 140-145 doi.org/10.1161/01.hyp.0000136134.31846.83
Bernatsky S., Hudson M., Suissa S. Antirheumatic drug use and risk of hospitalization for congestive heartfailure in rheumatoid arthritis. Rheumatology (Oxford), 2005; 44 (5): 677-680. doi: 10.1093/rheumatology/keh610
Morgan T., Anderson A., Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. American Journal of Hypertension. 2000; 13 (11): 1161-1167. doi: 10.1016/S0895-7061(00)01204-8
Strand V., Simon L.S., Dougados M., Sands, G.H., Bhadra, P., Breazna, A., Immitt J. Treatment of osteoarthritis with continuous versus intermittent celecoxib. The Journal of Rheumatology. 2011; 38(12):2625-2634. doi.org/10.3899/jrheum.110636
Tubaro E., Belogi L., Mezzadri C.M. The mechanism of action of amtolmetin guacyl, a new gastroprotective nonsteroidal anti-inflammatory drug. European Journal of Pharmacology. 2000; 387, 233-244. doi.org/10.1016/s0014-2999(99)00791-8
Coruzzi G., Coppelli G, Cavestro G.M., Okolicsanyi L., Pisano C., Tepperman В. Gastroprotective effects of amtolmetin guacyl: A new non steroidal antiinflammatory drug that activates inducible gastric nitric oxide synthase. Gastroenterology. 2000; 118 (4): A246. doi.org/10.1016/s0016-5085(00)83059-0
Jajic Z., Malaise M., Nekam K., Koó É., Dankó K., Kovacs M., Scarpignato C. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology. 2005; 23: 809-818
Tubaro E., Belogi L., Mezzadri C.M. Anti-inflammatory and antiplatelet effect of Amtolmetin Guacyl, a new gastroprotective non-steroidal anti-inflammatory drug. Arzneimittelforschung. 2001, 51: 737-742. doi.org/10.1055/s-0031-1300108
Gaidukova I.Z., Rebrov A.P., Aparkina A.V., Khondkaryan E.V. Efficacy and cardiovascular safety of amtolmetin guacyl (Nayzilat) in patients with ankylosing spondylitis: preliminary results of the research CORONA. Effektivnaya Farmakoterapiya, Revmatologiya, travmatologiya i ortopediya. 2015;3: 4-10